177 results match your criteria: "Clinic for Children and Adolescents[Affiliation]"

Gliomas are the most common and lethal forms of malignant brain tumors. We attempted to identify the role of the aging-suppressor gene and Klotho protein in the immunopathogenesis of gliomas. We examined genetic variants by PCR-RFLP and measured serum Klotho levels using the ELISA method.

View Article and Find Full Text PDF

Exercise has a significant impact on the cardiovascular (CV) health of children and adolescents, with resultant alterations in CV structure and function being evident, even at an early age. Engagement in regular, moderate physical activity (PA) is associated with long-term CV health benefits and a reduced risk of CV disease and mortality later in life. However, competitive sports often involve PA training intensities that are beyond recommended levels for young athletes, potentially leading to adverse CV outcomes.

View Article and Find Full Text PDF

A direct punch with a clenched fist to the face most often results in soft tissue damage, which is usually not serious enough to be considered a severe health impairment. This article presents two cases in which a single punch to the orbital region led to a blowout fracture. The first case resulted in additional displacement of the right lens into the vitreous body, secondary glaucoma and retinal detachment.

View Article and Find Full Text PDF
Article Synopsis
  • The study explores how overexpressing FGF23 affects SaOS-2 cells, particularly regarding stress responses and morphology, and its relation to skeletal disorders like X-linked hypophosphatemia (XLH).
  • Researchers utilized transmission electron microscopy and protein analysis to observe changes in the rough endoplasmic reticulum (rER) and mitochondria of these cells, noting significant alterations such as enlargement and increased contact zones.
  • The findings indicate higher rates of apoptosis and activation of pathways related to cellular stress, suggesting that FGF23 overexpression plays a critical role in how cells manage protein synthesis demands and stress, paving the way for potential therapeutic strategies for related diseases.
View Article and Find Full Text PDF

Clinical challenges in the dosing and titration of cariprazine.

Front Psychiatry

August 2024

Department of Psychiatry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

The introduction of a new psychopharmaceutical medication instead of the previous one always poses a certain challenge. In the case of antipsychotics (AP), these problems are considerably more complicated and are mainly caused by the question of dose equivalents, but also by the pharmacokinetic properties of the drug. In the case of partial dopamine D2 agonists, an additional issue is the possibility of deterioration when switching from the previous D2 antagonists to these drugs.

View Article and Find Full Text PDF

Background: Few studies have investigated the risk of psychiatric neurodevelopmental disorders (PNDD) after childhood meningitis.

Methods: Nationwide population-based cohort study (Denmark, 1995-2021) of children with positive cerebrospinal fluid for bacteria or enterovirus, stratified on age as young infants (0 to <90 days,  = 637) or older children (≥90 days to <17 years,  = 1,218). We constructed a comparison cohort from the general population ( = 18,550), and cohorts of siblings of participants.

View Article and Find Full Text PDF

Nocturnal Hypoglycemia in the Era of Continuous Glucose Monitoring.

J Diabetes Sci Technol

September 2024

Science Consulting in Diabetes GmbH, Düsseldorf, Germany.

Nocturnal hypoglycemia is a common acute complication of people with diabetes on insulin therapy. In particular, the inability to control glucose levels during sleep, the impact of external factors such as exercise, or alcohol and the influence of hormones are the main causes. Nocturnal hypoglycemia has several negative somatic, psychological, and social effects for people with diabetes, which are summarized in this article.

View Article and Find Full Text PDF

Background: Nocturnal hypoglycaemia is a burden for people with diabetes, particularly when treated with multiple daily injections (MDI) therapy. However, the characteristics of nocturnal hypoglycaemic events in this patient group are only poorly described in the literature.

Method: Continuous glucose monitoring (CGM) data from 185 study participants with type 1 diabetes using MDI therapy were collected under everyday conditions for up to 13 weeks.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to identify brain MRI patterns associated with pediatric genetic disorders linked to white matter abnormalities in Northern Finland, focusing on patients diagnosed before age 18.
  • Researchers reviewed MRI scans from Oulu University Hospital collected over 29 years, ultimately analyzing 83 patients with 52 different genetic conditions that showed significant white matter issues.
  • A majority (87%) of the children had abnormal MRI results, highlighting specific abnormalities like cerebral white matter changes and thinning of the corpus callosum, indicating that these patterns can help diagnose rare genetic disorders effectively.
View Article and Find Full Text PDF

Background: Approximately 10% of European children are classified as allergic to drugs. In the majority of these children, no allergy to β-lactam antibiotics (BLA) can be found. In most cases, the exanthema is caused by the infection.

View Article and Find Full Text PDF

We aimed to provide a detailed phenotypic description of status epilepticus (SE) in a large cohort of patients with POLG disease and identify prognostic biomarkers to improve the management of this life-threatening condition. In a multinational, retrospective study with data on patients with POLG disease from seven European countries, we identified those who had SE. The age of SE onset, accompanying clinical, laboratory, imaging and genetic findings were analysed.

View Article and Find Full Text PDF

Adiponectin, a hormone secreted by adipose tissue, plays a complex role in regulating metabolic homeostasis and has also garnered attention for its potential involvement in the pathogenesis of late-onset Alzheimer's disease (LOAD). The objective of this study was to investigate the association of variants with plasma adiponectin levels and LOAD risk in subjects from the Slovak Caucasian population. For this purpose, 385 LOAD patients and 533 controls without cognitive impairment were recruited and genotyped for a total of eighteen single nucleotide polymorphisms (SNPs).

View Article and Find Full Text PDF

Background: In a randomized controlled trial, the efficacy of a digital diabetes diary regarding a reduction of diabetes distress was evaluated.

Methods: A randomized controlled trial with a 12-week follow-up was conducted in 41 study sites across Germany. Key eligibility criteria were a diagnosis of type 1, type 2, or gestational diabetes and regular self-monitoring of blood glucose.

View Article and Find Full Text PDF

Objectives: This prospective multicenter study aimed (1) to examine changes in parent-reported health-related quality of life (HRQOL) of children with short stature and the effects of the children's condition on parents themselves within the first year of human growth hormone (hGH) treatment and (2) to predict based on main and interaction effects of children's HRQOL and increase in height.

Methods: A total of 110 parents of children aged 4-18 years, diagnosed with idiopathic growth hormone deficiency, small for gestational age, or idiopathic short stature, were recruited from 11 participating German pediatric endocrinologists and asked to fill out the short stature-specific Quality of Life in Short Stature Youth (QoLISSY) Questionnaire before hGH treatment was initiated and one year later.

Results: Negative effects of the children's short stature on the parents decrease over time, independent of diagnosis and treatment status.

View Article and Find Full Text PDF

We conducted a systematic review investigating the efficacy and tolerability of adrenocorticotropic hormone (ACTH) and corticosteroids in children with epilepsies other than infantile epileptic spasm syndrome (IESS) that are resistant to anti-seizure medication (ASM). We included retrospective and prospective studies reporting on more than five patients and with clear case definitions and descriptions of treatment and outcome measures. We searched multiple databases and registries, and we assessed the risk of bias in the selected studies using a questionnaire based on published templates.

View Article and Find Full Text PDF

Diagnostic evaluation of paediatric autoimmune lymphoproliferative immunodeficiencies (ALPID): a prospective cohort study.

Lancet Haematol

February 2024

Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. Electronic address:

Article Synopsis
  • The study investigates autoimmune lymphoproliferative syndrome (ALPS) and similar severe conditions characterized by lymphoproliferation and autoimmune cytopenias, aiming to better classify these disorders based on genetic and clinical features.
  • Conducted in Germany with 431 children referred for ALPS evaluation, the study categorized patients based on specific criteria related to lymphoproliferation and associated immune deficiencies, with a median diagnostic age of about 9.8 years.
  • Findings revealed that 55% of enrolled children were diagnosed with ALPS, and genetic assessments helped differentiate ALPS from autoimmune lymphoproliferative syndrome-like diseases, enhancing understanding and classification of these immune disorders.
View Article and Find Full Text PDF

Background: The incidence of inflammatory bowel disease (IBD) in children is on the increase worldwide. Growth disorders are common in pediatric patients with inflammatory bowel disease. The aim of this paper is to investigate anthropometric indicators, including height and weight in children with inflammatory bowel disease in Saxony, one of the German federal states, and to evaluate growth trends in patients by comparing their height and weight with that of healthy children in Germany.

View Article and Find Full Text PDF

Survival in primary hemophagocytic lymphohistiocytosis, 2016 to 2021: etoposide is better than its reputation.

Blood

March 2024

Center for Chronic Immunodeficiency, Institute for Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Primary hemophagocytic lymphohistiocytosis (pHLH) is a life-threatening hyperinflammatory syndrome that develops mainly in patients with genetic disorders of lymphocyte cytotoxicity and X-linked lymphoproliferative syndromes. Previous studies with etoposide-based treatment followed by hematopoetic stem cell transplantation (HSCT) resulted in 5-year survival of 50% to 59%. Contemporary data are lacking.

View Article and Find Full Text PDF
Article Synopsis
  • Hymenoptera venom (HV), injected by bees and wasps during stings, can cause allergic reactions in about 3% of people, leading to severe local or systemic allergic reactions in some cases.
  • The guidelines suggest that while symptomatic therapy is needed after a severe local reaction, specific allergen immunotherapy isn't necessary unless severe reactions occur beyond the skin.
  • Clinicians should assess patients for risk factors, measure tryptase levels if reactions are significant, and test for specific IgE antibodies to diagnose sensitization to Hymenoptera venom.
View Article and Find Full Text PDF

Natural History and Developmental Trajectories of Individuals With Disease-Causing Variants in .

Neurology

August 2023

From the Division of Pediatric Epileptology (K.M.T., J.H.D., A.S., J.S., S.S.), Pediatric Neurology and Metabolic Medicine (A.S., S.F.G., J.S., S.K., G.F.H., M.R.), Center for Pediatrics and Adolescent Medicine, University Hospital Heidelberg, Germany; The Epilepsy NeuroGenetics Initiative (ENGIN) (K.M.T., J.X., S.M.R., K.R.S., I.H.), Division of Neurology (J.X., S.M.R., K.R.S., I.H.), and Department of Biomedical and Health Informatics (DBHi) (J.X., I.H.), Children's Hospital of Philadelphia, PA; Epilepsy Center Kleinwachau (P.Z.), Radeberg, Germany; Department of Neuropediatrics and Children's Research Center (B.K.B., G.R.), University Children's Hospital Zurich, University of Zurich; Department of Pediatric Neurology (B.K.B.), Children's Hospital of Eastern Switzerland, Sankt Gallen; Department of Pediatric Neurology and Developmental Medicine (A.N.D.), University Children's Hospital Basel UKBB, Switzerland; Department of Neurology (C.K.), Klinikum Osnabrück; Epilepsy Center (C.K.), Münster-Osnabrück, Campus Osnabrück; Department of Pediatrics (J.A.), Christophorus Hospital Coesfeld; Epilepsy Center Kork (A.W.-K.), Clinic for Children and Adolescents, Kehl-Kork; Department of Neuropediatrics (A.v.B., M.L.), University Medical Center Schleswig-Holstein, Kiel University (CAU); Center for Social Pediatrics (A.P.), Johannes Wesling Klinikum Minden; Department of Pediatric Neurology and Developmental Medicine (M.A.), University Children's Hospital, Tübingen, Germany; Department of Pediatric Neurology (H.M.H.B.), Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, the Netherlands; Department of Pediatrics (O.M.D.), Clemenshospital Münster; Department of Pediatrics (J.D.), University Medical Center Hamburg-Eppendorf; Division of Pediatric Neurology (E.H.), Department of Pediatrics and Adolescent Medicine, University Medical Center Göttingen; Kinderärzte Ammersee (I. Breitweg), Neubruch 1, Inning an Ammersee; Department of Neuropediatrics (D.D.), University Hospital Giessen; Department of Neuropediatrics (H.E.), Klinikum Esslingen; Division of Neuropediatrics (J.G.-A.), Hospital for Children and Adolescents, University Hospital Leipzig, Germany; Department of Neuropediatrics (M.P.), Children University Hospital and Paracelsus Medical University, Salzburg, Austria; Department of Neuropediatrics (J.-U.S.), Gemeinschaftskrankenhaus Herdecke; Department of Pediatrics and Adolescent Medicine (D.M.), and Center for Social Pediatrics (D.M.), University Hospital Erlangen, Friedrich-Alexander-Universität (FAU); Department of Pediatric Neurology (C.W.), SRH Zentralklinikum Suhl; Department of Pediatric Neurology (C.P.), and Center for Chronically Sick Children (C.P.), Charité-Universitätsmedizin Berlin; Department of Pediatric Neurology (C.L.-N.), Klinikum Mutterhaus der Borromäerinnen gGmbH, Trier; Séguin-Clinic for Persons with Severe Intellectual Disability (P.M.), Epilepsy Centre Kork; Medical Faculty (P.M.), University of Freiburg; Institute of Human Genetics (K.P., J.R.L.), University of Leipzig Medical Center; Sana-Krankenhaus Düsseldorf-Gerresheim (I.B.-H.), Academic Teaching Hospital der Heinrich-Heine-University Düsseldorf; Department of Neuropediatrics (K.E.), Sankt Elisabeth, KJF Klinik, Neuburg an der Donau; Department of Neuropediatrics (W.F.), Children's Hospital, University of Bonn; Center of Rare Diseases (J.R.L.), University of Leipzig Medical Center; Klinikum Aschaffenburg-Alzenau (E.R.); Department of Neuropediatrics (B.K.), Klinikum Frankfurt Höchst GmbH; Department of Neuropediatrics (T.L.), University Children's Hospital, Klinikum Oldenburg; Department of Neuropediatrics (H.S.), Klinikum Wolfsburg; Kinderneurologie Thies (B.T.), Lüneburg; Sozialpädiatrisches Zentrum Coburg (F.v.D.); Clinic for Pediatric Kidney-, Liver- and Metabolic Diseases (S.I.), Hannover Medical School; Division of Pediatric Neurology and Developmental Medicine (I. Borggraefe), Department of Pediatrics, University Hospital of the Ludwig-Maximilians-University of Munich; Department of Pediatrics (G.C.), Evangelisches Klinikum Bethel, University Hospital Owl, University Bielefeld; Institute of Human Genetics (D.W.), Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Germany; and Department of Neurology (I.H.), University of Pennsylvania Perelman School of Medicine, Philadelphia.

Article Synopsis
  • The study investigates neurodevelopmental disorders caused by pathogenic variants, focusing on individuals without epilepsy, as little is known about their development and potential treatment endpoints beyond seizure control.
  • Researchers conducted a retrospective study collecting data from 71 individuals, including 44 new cases, assessing their medical histories and developmental outcomes using standardized measures.
  • Findings revealed that 25% of the participants did not have epilepsy, and those without it generally had better motor function and developmental outcomes, suggesting distinct clinical features between individuals with and without a history of seizures.
View Article and Find Full Text PDF

Objective: In Saxony, the incidence of Crohn's disease (CD) in children and adolescents increased significantly from 3.3 per 100,000 person-years in 2000 to 5.1 in 2014.

View Article and Find Full Text PDF

Facial Emotion Recognition in Patients with Juvenile Myoclonic Epilepsy.

J Clin Med

June 2023

Clinic for Children and Adolescents, Department of Neuropediatrics, Goethe-University, 60590 Frankfurt am Main, Germany.

Previous studies have found facial emotion recognition (FER) impairments in individuals with epilepsy. While such deficits have been extensively explored in individuals with focal temporal lobe epilepsy, studies on individuals with generalized epilepsies are rare. However, studying FER specifically in individuals with juvenile myoclonic epilepsy (JME) is particularly interesting since they frequently suffer from social and neuropsychological difficulties in addition to epilepsy-specific symptoms.

View Article and Find Full Text PDF
Article Synopsis
  • A study aimed to improve pediatric pharmacotherapy through a quality assurance measure called PaedPharm, which seeks to reduce medication-related hospitalizations in children and adolescents.
  • The PaedPharm intervention included a digital drug information system, professional quality circles, and an adverse drug event reporting system, and was tested in a cluster-randomized trial across 12 regions.
  • Results showed a reduction in adverse drug event-related hospitalizations, with a decrease from 4.1% to 3.1%, but the results were not statistically significant; however, the intervention was well-accepted by healthcare providers.
View Article and Find Full Text PDF